The DOI matches its Crossref record.
Cisplatin and platinum drugs at the molecular level (Review)
Abstract
Over twenty years of intensive work toward improvement of cisplatin, and with hundreds of platinum drugs tested, has resulted in the introduction of the widely used carboplatin and of oxaliplatin used only for a very narrow spectrum of cancers. A number of interesting platinum compounds including the orally administered platinum drug JM216, nedaplatin, the sterically hindered platinum(II) complex ZD0473, the trinuclear platinum complex BBR3464, and the liposomal forms Lipoplatin and SPI-77 are under clinical evaluation. This review summarizes the molecular mechanisms of platinum compounds for DNA damage, DNA repair and induction of apoptosis via activation or modulation of signaling pathways and explores the basis of platinum resistance. Cisplatin, carboplatin, oxaliplatin and most other platinum compounds induce damage to tumors via induction of apoptosis; this is mediated by activation of signal transduction leading to the death receptor mechanisms as well as mitochondrial pathways. Apoptosis is responsible for the characteristic nephrotoxicity, ototoxicity and most other toxicities of the drugs. The major limitation in the clinical applications of cisplatin has been the development of cisplatin resistance by tumors. Mechanisms explaining cisplatin resistance include the reduction in cisplatin accumulation inside cancer cells because of barriers across the cell membrane, the faster repair of cisplatin adducts, the modulation of apoptotic pathways in various cells, the upregulation in transcription factors, the loss of p53 and other protein functions and a higher concentration of glutathione and metallothioneins in some type of tumors. A number of experimental strategies to overcome cisplatin resistance are at the preclinical or clinical level such as introduction of the bax gene, inhibition of the JNK pathway, introduction of a functional p53 gene, treatment of tumors with aldose reductase inhibitors and others. Particularly important are combinations of platinum drug treatments with other drugs, radiation and the emerging gene therapy regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Castano, A. P., Demidova, T. N., & Hamblin, M. R. (2005) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/s1572-1000(05)00030-x · Cited by 767
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
Steichen, S. D., Caldorera-Moore, M., & Peppas, N. A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.006 · Cited by 751
Rajendiran, V., Karthik, R., Palaniandavar, M., Stoeckli-Evans, H., Periasamy, V. S., Akbarsha, M. A., Srinag, B. S., & Krishnamurthy, H. (2007) · Inorganic Chemistry · doi:10.1021/ic700755p · Cited by 589
Cisplatin Nephrotoxicity Is Critically Mediated via the Human Organic Cation Transporter 2
Ciarimboli, G., Ludwig, T., Lang, D., Pavenstädt, H., Koepsell, H., Piechota, H.-J., Haier, J., Jaehde, U., Zisowsky, J., & Schlatter, E. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61234-5 · Cited by 448
Therrien, B., Süss‐Fink, G., Govindaswamy, P., Renfrew, A. K., & Dyson, P. J. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800186 · Cited by 446
Metal-organic frameworks as potential drug delivery systems
Sun, C.-Y., Qin, C., Wang, X.-L., & Su, Z.-M. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.741583 · Cited by 408
Drug-Induced Acute Kidney Injury
Perazella, M. A., & Rosner, M. H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11290821 · Cited by 357
Liposomal encapsulated anti-cancer drugs
Hofheinz, R.-D., Gnad-Vogt, S. U., Beyer, U., & Hochhaus, A. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000167902.53039.5a · Cited by 355
Park, G. Y., Wilson, J. J., Song, Y., & Lippard, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207670109 · Cited by 330
Ali, B. H., & Al Moundhri, M. S. (2006) · Food and Chemical Toxicology · doi:10.1016/j.fct.2006.01.013 · Cited by 328
Han, R., Yang, Y. M., Dietrich, J., Luebke, A., Mayer-Pröschel, M., & Noble, M. (2008) · Journal of Biology · doi:10.1186/jbiol69 · Cited by 316
Ultrasound triggered release of cisplatin from liposomes in murine tumors
Schroeder, A., Honen, R., Turjeman, K., Gabizon, A., Kost, J., & Barenholz, Y. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.007 · Cited by 305
The roles of copper transporters in cisplatin resistance
Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9045-3 · Cited by 283
Barr, M. P., Gray, S. G., Hoffmann, A. C., Hilger, R. A., Thomale, J., O’Flaherty, J. D., Fennell, D. A., Richard, D., O’Leary, J. J., & O’Byrne, K. J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233739 · Cited by 269
Bhat, S. S., Kumbhar, A. A., Heptullah, H., Khan, A. A., Gobre, V. V., Gejji, S. P., & Puranik, V. G. (2011) · Inorganic Chemistry · doi:10.1021/ic101534n · Cited by 268
Advances in Platinum Chemotherapeutics
Harper, B. W., Krause‐Heuer, A. M., Grant, M. P., Manohar, M., Garbutcheon‐Singh, K. B., & Aldrich‐Wright, J. R. (2010) · Chemistry – A European Journal · doi:10.1002/chem.201000148 · Cited by 267
Brozovic, A., Ambriović-Ristov, A., & Osmak, M. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408441003601836 · Cited by 261
Long–Term Renal Outcomes after Cisplatin Treatment
Latcha, S., Jaimes, E. A., Patil, S., Glezerman, I. G., Mehta, S., & Flombaum, C. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08070715 · Cited by 256
Zhang, R., Song, X., Liang, C., Yi, X., Song, G., Chao, Y., Yang, Y., Yang, K., Feng, L., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.025 · Cited by 255
Lipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224
Self-citationShahid, F., Farooqui, Z., & Khan, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.009 · Cited by 166
Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy
Khasabova, I. A., Khasabov, S., Paz, J., Harding-Rose, C., Simone, D. A., & Seybold, V. S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0403-12.2012 · Cited by 129
Pastorino, F., Loi, M., Sapra, P., Becherini, P., Cilli, M., Emionite, L., Ribatti, D., Greenberger, L. M., Horak, I. D., & Ponzoni, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1354 · Cited by 79
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Herraez, E., Gonzalez-Sanchez, E., Vaquero, J., Romero, M. R., Serrano, M. A., Marin, J. J. G., & Briz, O. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300178a · Cited by 67
Induction of targeted necrosis with HER2-targeted platinum( iv ) anticancer prodrugs
Wong, D. Y. Q., Lim, J. H., & Ang, W. H. (2015) · Chemical Science · doi:10.1039/c5sc00015g · Cited by 40
Metadata
- Authors
- Boulikas, T., & Vougiouka, M.
- Venue
- Oncology Reports
- Publisher
- Spandidos Publications
- Published
- 2003-11-01
- Volume
- 10
- Issue
- 6
- Pages
- 1663-82
- ISSN
- 1021-335X (ISSN-L)
- 1791-2431
- OpenAlex
- W2071568301
- Cited by
- 729
- References
- 0
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.